PHARMACY

Navarro Discount Pharmacy supplies pink Rx bottles in support of Breast Cancer Awareness month

BY Antoinette Alexander

MIAMI and PEMBROKE PINES, Fla. — Regional pharmacy chain Navarro Discount Pharmacy, which operates 31 locations in south Florida, is supplying pink prescription bottle caps on all prescriptions filled during the month of October in support of Breast Cancer Awareness month, the company has announced.

“As a community pharmacy, we are focused on supporting activities that educate women, families and children about a variety of health issues,” stated Albert Garcia, EVP pharmacy operations at Navarro Discount Pharmacy.

The company supports and participates in several major breast cancer awareness charitable organizations, including the Susan B. Komen Foundation and the Liga Contra el Cancer (The League Against Cancer).

“Breast cancer is one of the leading causes of cancer death among women of all races, including Hispanic origin populations,” stated Cristy Leon-Rivero, VP marketing at Navarro Discount Pharmacy.

In addition to the pink prescription bottle caps, Navarro is using this as an opportunity to remind women to be aware and proactive in an effort to detect breast cancer earlier by conducting their own self-examinations. Breast cancer affects 1-out-of-8 women during their lives. It is the second-leading cancer killer of women in the United States, next to lung cancer. Thanks to screening and detection, breast cancer often can be found early, when the chance of successful treatment is highest.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
PHARMACY

Pharmaca launches mobile app

BY Alaric DeArment

BOULDER, Colo. — Pharmaca Integrative Pharmacy has launched a mobile app for patients to manage their prescriptions, the retail pharmacy chain said Tuesday.

The app, which operates on a secure network created by San Francisco-based Mscripts, includes dosage reminders, health information and features for getting prescription refills and pickup reminders. The company also launched a new mobile website, at M.pharmaca.com.

"Pharmaca has always provided customers with innovative solutions for their health needs," Pharmaca VP pharmacy operations Stuart Gratz said. "This new app makes it easy to manage prescriptions and health information, allowing customers to communicate with us in a variety of ways. It also emphasizes our commitment to green initiatives; knowing the status of their refills reduces unnecessary trips to the pharmacy and allows our customers to maximize their time while they are in the store."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
PHARMACY

United Therapeutics awaits FDA decision on oral PAH drug as Sandoz seeks generic approval

BY Alaric DeArment

NEW YORK — The Food and Drug Administration is expected to decide at the end of this week whether to approve a new oral drug for pulmonary arterial hypertension made by United Therapeutics.

The FDA is scheduled to reach its decision this Saturday on United Therapeutics’ treprostinil diethanolamine sustained-release tablets for PAH, a potentially fatal disease that causes high blood pressure in the blood vessels of the lungs, according to the company. The company already markets inhaled and injected formulations of the drug under the brand names Tyvaso and Remodulin, respectively.

Meanwhile, Sandoz, the generics arm of Swiss drug maker Novartis, is seeking to market a generic version of Remodulin. United Therapeutics filed a lawsuit against Sandoz in March after the generic drug maker filed for approval of generic treprostinil injection in the 10-mL-per-mg strength. Sandoz said three patents covering Remodulin are invalid, unenforceable or won’t be infringed; United Therapeutics’ lawsuit puts a stay of final FDA approval on the generic version for up to 30 months. The patents are scheduled to expire between 2014 and 2029, according to FDA records.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...